EDGAR Filing Documents for 0001437749-23-016520

Form 8-K - Current report:

SEC Accession No. 0001437749-23-016520

Filing Date

2023-06-05

Accepted

2023-06-02 18:14:52

Documents

Period of Report

2023-06-01

Items

Item 1.01: Entry into a Material Definitive Agreement
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.02: Unregistered Sales of Equity Securities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Interactive Data

Document Format Files

Seq	Description	Document	Type	Size
1	FORM 8-K	navb20230602_8k.htm iXBRL	8-K	40219
2	EXHIBIT 10.1	ex_529276.htm	EX-10.1	33756
3	EXHIBIT 99.1	ex_529357.htm	EX-99.1	15449
4	EXHIBIT 99.2	ex_529366.htm	EX-99.2	12757
5	EXHIBIT 99.3	ex_529291.htm	EX-99.3	8154
	Complete submission text file	0001437749-23-016520.txt		283547

Data Files

Seq	Description	Document	Type	Size
6	XBRL TAXONOMY EXTENSION SCHEMA	navb-20230601.xsd	EX-101.SCH	4034
7	XBRL TAXONOMY EXTENSION DEFINITION LINKBASE	navb-20230601_def.xml	EX-101.DEF	13505
8	XBRL TAXONOMY EXTENSION LABEL LINKBASE	navb-20230601_lab.xml	EX-101.LAB	17659
9	XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE	navb-20230601_pre.xml	EX-101.PRE	13472
11	EXTRACTED XBRL INSTANCE DOCUMENT	navb20230602_8k_htm.xml	XML	4288

Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017

Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500

NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)